Chris J. Edgar, United Kingdom
Cogstate Clinical scienceAuthor Of 2 Presentations
VALIDITY AND SENSITIVITY OF THE COGSTATE BRIEF BATTERY FOR IN-CLINIC AND AT-HOME COGNITIVE ASSESSMENT IN ADNI-3
Abstract
Aims
The Cogstate Brief Battery (CBB) is a computerized cognitive assessment validated for Alzheimer’s disease (AD) and unsupervised use. The CBB assesses processing speed, attention, visual learning, and working memory. The CBB is offered to cognitively normal (CN) and mild cognitive impairment (MCI) participants in ADNI-3. In-clinic visits are completed annually for MCI and every other year for CN, with both groups completing unsupervised assessments at-home within 14 days of the first in-clinic visit and every 3 months.
Methods
CBB data were analyzed for eight outcome measures to evaluate sensitivity to disease status (CN, MCI), effect of setting (in-clinic, at-home), and change over time.
Results
Data were analyzed for 697 participants (459 CN, 222 MCI, 12 AD). Fewer participants completed a first at-home (n=365) versus a first in-clinic assessment (n=629). Statistically significant, small-moderate effect size differences between CN and MCI/AD (0.34 to 0.72) were evident at the first in-clinic visit. Effect size differences for in-clinic versus first at-home assessment, were small (<0.01 to 0.29) and non-significant, except for faster working memory reaction times at-home. Linear mixed models for participants completing 24 months (n=171), showed evidence for divergence between CN and MCI over time, a finding most evident on the learning and memory tests. Inclusion of amyloid status supported a predicted pattern of poorer cognition in amyloid positive participants.
Conclusions
Data from ADNI-3 support the validity and sensitivity of the CBB for unsupervised, at-home assessment, demonstrating known groups validity, equivalence between in-clinic and at-home assessment, and longitudinal sensitivity.
LIVE DISCUSSION
Presenter of 2 Presentations
VALIDITY AND SENSITIVITY OF THE COGSTATE BRIEF BATTERY FOR IN-CLINIC AND AT-HOME COGNITIVE ASSESSMENT IN ADNI-3
Abstract
Aims
The Cogstate Brief Battery (CBB) is a computerized cognitive assessment validated for Alzheimer’s disease (AD) and unsupervised use. The CBB assesses processing speed, attention, visual learning, and working memory. The CBB is offered to cognitively normal (CN) and mild cognitive impairment (MCI) participants in ADNI-3. In-clinic visits are completed annually for MCI and every other year for CN, with both groups completing unsupervised assessments at-home within 14 days of the first in-clinic visit and every 3 months.
Methods
CBB data were analyzed for eight outcome measures to evaluate sensitivity to disease status (CN, MCI), effect of setting (in-clinic, at-home), and change over time.
Results
Data were analyzed for 697 participants (459 CN, 222 MCI, 12 AD). Fewer participants completed a first at-home (n=365) versus a first in-clinic assessment (n=629). Statistically significant, small-moderate effect size differences between CN and MCI/AD (0.34 to 0.72) were evident at the first in-clinic visit. Effect size differences for in-clinic versus first at-home assessment, were small (<0.01 to 0.29) and non-significant, except for faster working memory reaction times at-home. Linear mixed models for participants completing 24 months (n=171), showed evidence for divergence between CN and MCI over time, a finding most evident on the learning and memory tests. Inclusion of amyloid status supported a predicted pattern of poorer cognition in amyloid positive participants.
Conclusions
Data from ADNI-3 support the validity and sensitivity of the CBB for unsupervised, at-home assessment, demonstrating known groups validity, equivalence between in-clinic and at-home assessment, and longitudinal sensitivity.
LIVE DISCUSSION